DEF: Lexeo Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Lexeo Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 26, 2025, featuring proposals for director elections and ratification of the independent accounting firm.

Summary

• Lexeo Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 26, 2025, at 10:00 a.m. Eastern.
• Stockholders as of the record date of May 7, 2025, are entitled to vote.
• The meeting will address the election of Steven Altschuler and Reinaldo Diaz as Class II directors, with terms expiring in 2028.
• The ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, will also be voted on.
• The board recommends voting FOR the election of the director nominees and FOR the ratification of the accounting firm appointment.
• As of April 25, 2025, there were 33,196,997 shares of common stock outstanding.
• The company is furnishing proxy materials primarily over the Internet to expedite receipt and lower costs.
• The notice of internet availability of proxy materials was first sent on or about May 12, 2025.
• The board of directors currently consists of eight members divided into three classes serving staggered three-year terms.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The positive aspects include the company's commitment to good corporate governance and shareholder engagement. The sentiment is slightly positive due to the routine nature of the announcements and the absence of any significant negative news.

Positives

• The company is using internet distribution of proxy materials to expedite receipt by stockholders, lower the cost of the Annual Meeting and conserve natural resources.
• The board has a compensation committee and has the right, in its sole discretion, to retain or obtain the advice of compensation consultants, independent legal counsel and other advisers to assist the compensation committee.
• The board has adopted corporate governance guidelines and a code of business conduct and ethics.
• The company has entered into indemnification agreements with each of its directors and executive officers.

Negatives

• As a result of the classification of directors, it generally takes at least two annual meetings of stockholders for stockholders to effect a change in a majority of the members of our board of directors.
• The company did not historically have a written policy for the review and approval of transactions with related parties.

Risks

• The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty.
• The company is a clinical stage precision oncology company.

Future Outlook

The proxy statement outlines proposals for the election of directors and ratification of the accounting firm, indicating a focus on corporate governance and financial oversight for the upcoming fiscal year.

Management Comments

• We are pleased to invite you to attend the 2025 Annual Meeting Stockholders of Lexeo Therapeutics, Inc.
• Thank you for your ongoing support of and continued interest in Lexeo Therapeutics, Inc.

Industry Context

This announcement is typical for publicly traded companies as they prepare for their annual meetings, ensuring compliance with SEC regulations and providing shareholders with the opportunity to vote on key company matters.

Comparison to Industry Standards

• The director compensation policy, including initial and annual grants of stock options, is generally in line with industry practices for biopharmaceutical companies of similar size and stage.
• The virtual format of the annual meeting aligns with a growing trend among public companies to enhance accessibility and reduce costs.
• The company's engagement of Alpine Rewards, LLC as a compensation consultant is a common practice to ensure executive compensation is competitive and aligned with performance.

Management Changes

Related Party Transactions

• Dr. Eric Adler, our Chief Medical Officer and Head of Research and an executive officer, was a co-founder of Stelios and a selling shareholder. Of the $6.0 million milestone payment, Dr. Adler received approximately $1.3 million.
• We are party to an amended and restated investors rights agreement with certain holders of our capital stock, including entities affiliated with D1 Capital Partners L.P., Eventide Healthcare & Life Sciences Fund, Longitude Capital Partners IV, LLC (where Reinaldo Diaz, a member of our board of directors, previously served as a Venture Partner), Lundbeckfond Invest A/S, and Omega Fund VI, L.P.
• In connection with our initial public offering, which closed on November 11, 2023, certain of our then related parties purchased shares of our common stock from the underwriters at the initial public offering price of $11.00 per share, on the same terms as other investors in our initial public offering.
• On March 11, 2024, we entered into a Common Stock Purchase Agreement (the Purchase Agreement) for a private placement (the Private Placement) with certain qualified institutional buyers and institutional accredited investors (each, a Purchaser and collectively, the Purchasers), which Purchasers included certain of our then related parties.

Stakeholder Impact

• Shareholders have the opportunity to vote on key decisions regarding the company's leadership and financial oversight.
• The election of directors and ratification of the accounting firm directly impact the company's governance and financial stability.
• The virtual format of the annual meeting aims to increase accessibility for all stockholders.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold the Annual Meeting on June 26, 2025, to address the proposals.
• The company will disclose voting results on a Current Report on Form 8-K that we will file with the SEC within four business days after the meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, KPMG, Stockholders, Governance, Compensation, Lexeo Therapeutics